Overview

Chemoimmunotherapy and Radiation in Pancreatic Cancer

Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety of combination treatment that includes chemotherapy, radiation therapy, and immunotherapy in patients with pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Providence Health & Services
Collaborator:
Eli Lilly and Company
Treatments:
Gemcitabine
Tadalafil